Donald P. Braun Purchases 25,000 Shares of Imunon, Inc. (NASDAQ:IMNN) Stock

Imunon, Inc. (NASDAQ:IMNN) Director Donald P. Braun bought 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $1.18 per share, for a total transaction of $29,500.00. Following the transaction, the director now owns 25,597 shares of the company’s stock, valued at $30,204.46. The trade was a 4,187.60 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Imunon Trading Down 2.5 %

Shares of NASDAQ:IMNN opened at $0.91 on Wednesday. Imunon, Inc. has a 12-month low of $0.48 and a 12-month high of $3.65. The business has a 50 day moving average of $0.87 and a two-hundred day moving average of $1.02. The company has a market capitalization of $13.25 million, a PE ratio of -0.48 and a beta of 2.04.

Imunon (NASDAQ:IMNN) last posted its earnings results on Thursday, November 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.03. During the same quarter last year, the firm earned ($0.37) earnings per share. Equities research analysts predict that Imunon, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Imunon in a report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Imunon in a report on Thursday, December 19th.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.